Trial Profile
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs Belapectin (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Proof of concept
- 02 Jun 2023 Status changed from active, no longer recruiting to completed.
- 24 Jan 2023 According to Galectin Therapeutics media release, this trial has provided a strong rationale for moving forward into a company sponsored phase II development program.
- 13 Jul 2022 Planned primary completion date changed from 1 May 2022 to 1 May 2023.